Alginate encapsulated cells secreting Fas‐ligand reduce lymphoma carcinogenicity

Fas ligand (CD95L/APO‐1) is considered as a potent anti‐tumor agent due to its mediated cell death properties. We have designed a polymeric microencapsulation system, which encapsulates soluble FasL secreting cells. The encapsulated cells continuously release soluble FasL (sFasL) at the tumor site,...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer science 2012-01, Vol.103 (1), p.116-124
Hauptverfasser:	Goren, Amit, Gilert, Ariel, Meyron‐Holtz, Esther, Melamed, Doron, Machluf, Marcelle
Format:	Artikel
Sprache:	eng
Schlagworte:	Alginates - therapeutic use Alginic acid Animals Antitumor agents Apoptosis Apoptosis - drug effects Biocompatible Materials - therapeutic use Biological activity Blotting, Western Cancer Cancer therapies Carcinogenicity CD95 antigen Cell Cycle - drug effects Cell death Cell proliferation Cell Proliferation - drug effects Cells Cytotoxicity Fas antigen Fas Ligand Protein - genetics Fas Ligand Protein - metabolism Fas Ligand Protein - therapeutic use FasL protein Fluorescent Antibody Technique Humans Immune system Immunoenzyme Techniques Ligands Lymphoma Lymphoma, T-Cell - immunology Lymphoma, T-Cell - pathology Lymphoma, T-Cell - prevention & control Male Mice Mice, Inbred DBA Mice, SCID Microcapsules Microencapsulation Original Penicillin Poly-L-lysine Polylysine - analogs & derivatives Polylysine - therapeutic use Real-Time Polymerase Chain Reaction RNA, Messenger - genetics Side effects Signal transduction Sodium Tumor cells Tumor Cells, Cultured Tumor necrosis factor-TNF Tumors
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!